Champions Oncology, Inc. · NASDAQ:CSBR
Champions Oncology — Investor Presentation (March 2016)
24 slides from Champions Oncology's investor presentation, Mar 7, 2016
Slide 1: Investor Presentation March 2016
1 Investor Presentation March 2016
Slide 2: Notice of Forward Looking Statements
2 Notice of Forward Looking Statements This presentation contains certain “forward - looking statements,” which include information relating to future events, future financial performance, strategies, expectations, competitive environment, regulation, and availability of resources . These forward -
Slide 3: Why Invest in Champions Oncology?
3 Why Invest in Champions Oncology? Innovation Innovative technology platform Market Size Large and growing market size Experience Experienced management team Progress 5 years of progress
Slide 4: Our Senior Management Team
4 Our Senior Management Team Joel Ackerman 15 years at Warburg Pincus investing in healthcare Board of Directors: Coventry Healthcare, Kindred Healthcare CEO David Sidransky, MD Johns Hopkins University, Professor and Director Head and Neck Cancer Research; Former Vice Chairman, Imclone Systems Chai
Slide 5: The Problem with Oncology Drugs
5 The Problem with Oncology Drugs Despite Advances, Response Rates Remain Low Skyrocketing R&D Investment Contributes to High Cost Failure Rates Remain High Clinical Evidence Doesn’t Mean Clinical Value $1.2 billion average capital outlay per approved biopharmaceutical Payers and physicians question
Slide 6: The Challenges of Clinical Trials in Oncology
6 The Challenges of Clinical Trials in Oncology Cost per patient: > $100,000 Participation Rate: < 5% CHALLENGE Clinical Trial Simulation Platform NEED
Slide 7: Simulating Patient Response to Oncology Drugs with Patient Derived Xenografts (PDX)
7 ✔ Simulating Patient Response to Oncology Drugs with Patient Derived XenoGrafts (PDX) Mice are dosed with different anti - tumor therapies Patient tumor is implanted in immune - compromised mice The effect of each therapy on tumor growth is measured χ χ χ Patient Implant Treatment Measurement
Slide 8: The Predictive Power of PDX
8 The Predictive Power of PDX A growing body of evidence demonstrates positive predictive value for Champions TumorGraft® PDX models. Clinical Accuracy Measures Result 95% Cl Positive Predictive Value (PPV) 87% (80/92) 77% - 93% Negative Predictive Value (NPV) 94% (32/34) 79% - 99% Source: 126 Tumor
Slide 9: Champions TumorGraft is an Immortalized Model of an Individual Patient
9 Champions TumorGraft is an Immortalized Model of an Individual Patient for Predicting Response Patient Data Perpetual Tissue Stock Genomic Data
Slide 10: The Champions TumorGraft Platform Today
10 The Champions TumorGraft® Platform Today 700 PDX models in our tumor bank that reflect characteristics of patients who enroll in clinical trials (late stage, pretreated and metastic)
Slide 11: Trial Simulation Process Using Champions' Platform
11 Reporting Study Design Dosing Model Establishment Work with customer to select patients from the TumorBank. Implant mice from selected models and ensure growth. Measure tumor size and report results to customer. Dose mice with experimental drugs, control groups and combinations. Trial Simulation
Slide 12: The Value of Patient Derived Xenografts
12 The Value of Patient Derived Xenografts Economics 90%+ lower costs than a human clinical trial PDX Repeatability Same patient can be run with multiple drugs for head - to - head comparisons Speed 6 months to study completion versus 2 - 3 years for human trial Predictability 90%+ accuracy in predi
Slide 13: Champions Built a Successful Core Business
13 Champions Built a Successful Core Business ~$50 Million Cumulative Revenue ~ 100 Customers Including 16 of the top 20 Pharma companies and 84 other pharma and biotech c ompanies 34% Core Revenue Growth Rate
Slide 14: Champions' Mission
14 Champions’ Mission “Pioneering the use of Patient Derived Xenografts to revolutionize the development and use of oncology drugs .”
Slide 15: Three Strategies for Accelerating Revenue Growth
15 Three Strategies for Accelerating Revenue Growth Immune Oncology Grow the Platform Innovative Study Designs
Slide 16: Novel Approaches to Grow the Breadth and Depth of the Tumor Bank
16 Champions is Employing Novel Approaches to Grow the Breadth and Depth of the Tumor Bank Deepening the Bank Research Custom Model Development Patients Broadening the Bank
Slide 17: Champions ImmunoGraft Development
17 Champions ImmunoGraft ™ Development A novel platform using Champions TumorGraft platform in humanized mice Proliferating human immune cells measured Screening against immuno - oncology agents Murine immune system eradicated and human immune system implanted Tumors from patients or banked tumors i
Slide 18: Innovative Study Designs Enable Larger Studies
18 Pre - clinical Phase 1 Phase 2 Phase 3 $0 $30 $60 $90 $120 $150 Cost Per Drug by Phase ($ millions) $150 $488 $690 $0 $500 $1,000 $1,500 Total Available Market Size 1 ($ millions) 1 Company estimates Innovative Study Designs Enable Larger Studies Recent bookings will drive accelerated revenue gro
Slide 19: Capturing More of the Value Created
19 Capturing More of the Value Created Platform License Data Fee for Service Milestones and Royalties Upside Potential Labor Intensive Low Low High High
Slide 20: Champions Operational Capabilities
20 Champions Operational Capabilities Corporate Headquarters Hackensack, NJ Approximately 70 FTEs 20MDs or PhDs Primary Lab & Vivarium Baltimore, MD Johns Hopkins Science + Technology Center AAALAC accredited ISO 9001:2008 certified CLIA certified Facility Breakdown 8,000 square feet 8 procedure roo
Slide 21: Upcoming Milestones
21 Upcoming Milestones Revenue acceleration from clinical deals AML revenue and gross margin Commercialization of ImmunoGraft product Cash flow positive Industry partnerships and collaborations
Slide 22: Historical Revenue Growth of Core TOS Business
22 $0 $1,000,000 $2,000,000 $3,000,000 $4,000,000 $5,000,000 $6,000,000 $7,000,000 $8,000,000 F2010 F2015 Historical Revenue Growth of Core TOS Business $0 $1,000,000 $2,000,000 $3,000,000 $4,000,000 $5,000,000 $6,000,000 H1 F2015 H1 F2016
Slide 23: Capital Markets Information
23 Ticker: CSBR (NASDAQ) Shares outstanding Primary: 8.7 million Warrants: 2.1 million Options: 2.0 million Cash (as of 10/31/15): $4.2 million Debt: Zero Quarterly burn rate: < $1 million per quarter Capital Markets Information
Slide 24: Champions Oncology
24 CHAMPIONS ONCOLOGY One University Plaza | Suite 307 Hackensack, NJ OUR EMAIL sforeman@championsoncology.com OUR PHONE 201.808.8400 OUR WEBSITE www.championsoncology.com
Champions Oncology — Investor Presentation (March 2016) on 6ix